Analysts Set Replimune Group, Inc. (NASDAQ:REPL) PT at $12.00

Shares of Replimune Group, Inc. (NASDAQ:REPL) have earned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $12.00.

A number of analysts have recently issued reports on REPL shares. Weiss Ratings downgraded shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research report on Tuesday, June 30th. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $11.00 to $17.00 in a research note on Tuesday, August 4th. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, August 26th. Finally, Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a research report on Friday, August 7th.

Replimune Group Stock Up 4.7%

Replimune Group stock opened at $13.47 on Friday. The firm has a 50 day moving average price of $12.83 and a 200-day moving average price of $9.08. Replimune Group has a twelve month low of $1.50 and a twelve month high of $16.33. The company has a market capitalization of $1.26 billion, a P/E ratio of -4.28 and a beta of 0.94. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 1.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). As a group, equities analysts predict that Replimune Group will post -2.81 EPS for the current year.

Insider Buying and Selling

In related news, CFO Emily Hill sold 9,256 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $14.28, for a total transaction of $132,175.68. Following the completion of the sale, the chief financial officer directly owned 215,852 shares in the company, valued at $3,082,366.56. This represents a 4.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Sushil Patel sold 39,341 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 79,124 shares of company stock valued at $1,038,364. 5.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Opaleye Management Inc. purchased a new position in shares of Replimune Group in the second quarter valued at about $15,332,000. WINTON GROUP Ltd purchased a new stake in shares of Replimune Group during the second quarter worth about $115,000. Engineers Gate Manager LP grew its stake in shares of Replimune Group by 15.0% in the second quarter. Engineers Gate Manager LP now owns 172,998 shares of the company’s stock worth $1,915,000 after purchasing an additional 22,504 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in shares of Replimune Group in the second quarter worth about $151,000. Finally, Squarepoint Ops LLC purchased a new position in Replimune Group during the 2nd quarter valued at about $1,454,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a biotechnology company focused on developing oncolytic immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach is based on a proprietary platform that uses genetically engineered herpes simplex virus type 1 (HSV-1) to selectively replicate in tumors and deliver immune-activating payloads.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an investigational oncolytic immunotherapy being evaluated in clinical studies for solid tumors, including melanoma and cutaneous squamous cell carcinoma.